Loading...

IBIO IBIO INC Product Launches 8-K Filing

B NC

B

IBIO INC

(IBIO)

2025 8-K

Show Summary

Summary

Notice of Delisting

Investor Meetings

Debt-Equity Swaps

Financial Statements

License Agreement

Corporate Update

Product Data Release

Earnings Report

Share Placement

Corporate Update

License Agreement

Director Appointments

Financial Results

Corporate Presentation

Financial Results

Departure of Directors or C...

Award Agreements and Code o...

Entry Into a Material Defin...

Termination and Sale

Filing with Quantitative Data

Property Sale and Loan Sett...

Financial Results Announcement

Securities Purchase Agreeme...

Financial Update

Credit and Security Agreement

Regulation FD Disclosure

Credit Agreement Amendment

Public Offering

Securities Purchase Agreeme...

Reverse Stock Split

Agreement Amendment

Agreement Amendment, Financ...

Purchase Agreement with Lin...

Appointment of CEO and CFO

Promissory Note Issued

Regulation FD Disclosure

Credit Agreement Amendment

Regulation FD Disclosure

Amendment to Credit Agreeme...

Management Appointments

Resignation of Officer

External Links:

On April 7, 2025, iBio, Inc. announced positive results from a non-human primate study of its anti-myostatin antibody IBIO-600, showing a half-life of 40 to 52 days and potential human half-life of 130 days, along with promising preclinical data for an Activin E antibody that led to significant weight loss in mice.

AI Assistant

IBIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.